Cargando…

Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast pathology

BACKGROUND: Recent clinical evidence showed that breast cancer with low HER2 expression levels responded to trastuzumab deruxtecan therapy. The HER2-low cancers comprise immunohistochemistry (IHC) score 1+ and 2+ ISH non-amplified tumours, currently classified as HER2 negative. Little data exists on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaakouk, Mohamed, Quinn, Cecily, Provenzano, Elena, Boyd, Clinton, Callagy, Grace, Elsheikh, Soha, Flint, Joe, Millican-Slater, Rebecca, Gunavardhan, Anu, Mir, Yasmeen, Makhija, Purnima, Di Palma, Silvana, Pritchard, Susan, Tanchel, Bruce, Rakha, Emad, Atallah, Nehal M., Lee, Andrew H.S., Pinder, Sarah, Shaaban, Abeer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382984/ https://www.ncbi.nlm.nih.gov/pubmed/37419078 http://dx.doi.org/10.1016/j.breast.2023.06.005

Ejemplares similares

Impact of COVID-19 on the practice of breast pathologists: a survey of breast pathologists in the UK and Ireland
por: Elghobashy, Mirna, et al.
Publicado: (2023)

Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma—A Large Multi-Institutional International Study
por: Zaakouk, Mohamed, et al.
Publicado: (2023)

The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry‐equivocal invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2022)

Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
por: Rakha, Emad A., et al.
Publicado: (2021)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Pitfalls in breast pathology
por: Quinn, Cecily, et al.
Publicado: (2022)

Clinical, Histopathologic Features and Outcome of Breast Cancer in UK Women of Ethnic Origin
por: Zaakouk, Mohamed, et al.
Publicado: (2022)

Refining the definition of HER2‐low class in invasive breast cancer
por: Atallah, Nehal M, et al.
Publicado: (2022)

Potential quality pitfalls of digitalized whole slide image of breast pathology in routine practice
por: Atallah, Nehal M., et al.
Publicado: (2021)

An update on the pathological classification of breast cancer
por: Rakha, Emad A, et al.
Publicado: (2022)

Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
por: Cserni, Gábor, et al.
Publicado: (2021)

Spindle cell lesions of the breast: a diagnostic approach
por: Rakha, Emad A., et al.
Publicado: (2021)

Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
por: Ahn, Soomin, et al.
Publicado: (2021)

Updated UK Recommendations for HER2 assessment in breast cancer
por: Rakha, Emad A, et al.
Publicado: (2015)

Communication with and on Behalf of Patients
por: Cheatham, Melvin L.
Publicado: (2013)

Apology on behalf of the publisher
Publicado: (2016)

Response in Behalf of the Graduates
por: Ward, B. B.
Publicado: (1859)

Reply on Behalf of the Class
por: Lathrop, H. K.
Publicado: (1870)

Problems for Pathologists
Publicado: (1876)

The Pathologist as Poet
por: Domen, Ronald E.
Publicado: (2016)

To be or not to be an oral pathologist
por: Ramesh, V
Publicado: (2019)

Pathologists’ Fees
Publicado: (1885)

On behalf of CERN's scientific community
Publicado: (1991)

On Behalf of European and Indian Lepers
por: Carleton, M. B.
Publicado: (1898)

Reply on Behalf of the Class of 1874
por: Mosher, Geo. H.
Publicado: (1874)

HIMSS10 – Perspectives from a newcomer pathologist and a seasoned attendee pathologist: Pathologists should attend!
por: Carter, Alexis B., et al.
Publicado: (2010)

Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis
por: Shiino, Sho, et al.
Publicado: (2022)

Review by urological pathologists improves the accuracy of Gleason grading by general pathologists
por: Nakai, Yasushi, et al.
Publicado: (2015)

Clinicopathologic and molecular predictors of axillary lymph node metastasis in early-stage breast cancer: a mathematical predictive model
por: Aleskandarany, MA, et al.
Publicado: (2010)

Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network)
por: Sebbag, Clara, et al.
Publicado: (2022)

Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1
por: Rakha, E A, et al.
Publicado: (2004)

Sentinel Lymph Node in Breast Cancer: Review Article from a Pathologist’s Point of View
por: Apple, Sophia K.
Publicado: (2016)

Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays
por: Akbar, Shazia, et al.
Publicado: (2015)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Georgios Chatzikonstantinidis on behalf of the LHCb collaboration
por: Chatzikonstantinidis, Georgios
Publicado: (2018)

General Evidence on Behalf of Mrs. Cumming
Publicado: (1852)

A Bugs Battle on Behalf of the Liver
por: Machado, Mariana Verdelho
Publicado: (2016)

An Appeal to the Public on Behalf of Sick Children
Publicado: (1850)

Association of Clinical Pathologists
Publicado: (2002)

The Relationship of the Pathologist to the Surgeon
Publicado: (1905)

Cannot write session to /tmp/vufind_sessions/sess_l2molohr79fvs1mcflfbsbejhp